PURPOSE: To describe the course of cytomegalovirus (CMV) retinitis in patients with AIDS in the era of highly active antiretroviral therapy (HAART). DESIGN: Multicenter, prospective, observational study. PARTICIPANTS: Two hundred seventy-one patients with AIDS and CMV retinitis. METHODS: Follow-up every 3 months with medical history, ophthalmologic examination, laboratory testing, and fundus photographs. MAIN OUTCOME MEASURE: Second (contralateral) eye involvement among patients with unilateral disease and retinal detachment (RD). RESULTS: The overall rate of second eye involvement among patients with unilateral CMV retinitis was 0.07 per person-year (PY); among those with CD4+ T-cell counts of <50/microl it was 0.34/PY, compared with 0.02/PY among those with CD4+ T-cell counts of > or =200/microl (P<0.0001). Risk factors for contralateral eye involvement included low CD4+ T-cell count and detectable CMV load. The overall rate of RD was 0.06/PY; among those with CD4+ T-cell counts of <50/microl it was 0.30/PY, compared with 0.02/PY among those with CD4+ T-cell counts of > or =200/microl (P<0.0001). Risk factors for RD included a low CD4+ T-cell count and larger area of CMV retinitis. CONCLUSIONS: Compared with the rates reported in the pre-HAART era of second eye involvement (approximately 0.40/PY) and RD (approximately 0.50/PY), the rates of these events were reduced among patients in the HAART era. However, among patients with CD4+ T-cell counts of <50/microl, the rates were more similar to those from the pre-HAART era.
PURPOSE: To describe the course of cytomegalovirus (CMV) retinitis in patients with AIDS in the era of highly active antiretroviral therapy (HAART). DESIGN: Multicenter, prospective, observational study. PARTICIPANTS: Two hundred seventy-one patients with AIDS and CMV retinitis. METHODS: Follow-up every 3 months with medical history, ophthalmologic examination, laboratory testing, and fundus photographs. MAIN OUTCOME MEASURE: Second (contralateral) eye involvement among patients with unilateral disease and retinal detachment (RD). RESULTS: The overall rate of second eye involvement among patients with unilateral CMV retinitis was 0.07 per person-year (PY); among those with CD4+ T-cell counts of <50/microl it was 0.34/PY, compared with 0.02/PY among those with CD4+ T-cell counts of > or =200/microl (P<0.0001). Risk factors for contralateral eye involvement included low CD4+ T-cell count and detectable CMV load. The overall rate of RD was 0.06/PY; among those with CD4+ T-cell counts of <50/microl it was 0.30/PY, compared with 0.02/PY among those with CD4+ T-cell counts of > or =200/microl (P<0.0001). Risk factors for RD included a low CD4+ T-cell count and larger area of CMV retinitis. CONCLUSIONS: Compared with the rates reported in the pre-HAART era of second eye involvement (approximately 0.40/PY) and RD (approximately 0.50/PY), the rates of these events were reduced among patients in the HAART era. However, among patients with CD4+ T-cell counts of <50/microl, the rates were more similar to those from the pre-HAART era.
Authors: Douglas A Jabs; Alka Ahuja; Mark Van Natta; Alice Lyon; Sunil Srivastava; Sapna Gangaputra Journal: Ophthalmology Date: 2010-07-29 Impact factor: 12.079
Authors: Douglas A Jabs; Alka Ahuja; Mark L Van Natta; Alice T Lyon; Steven Yeh; Ronald Danis Journal: Ophthalmology Date: 2015-04-17 Impact factor: 12.079
Authors: Igor Kozak; Vijay Vaidya; Mark L Van Natta; Jeong W Pak; K Patrick May; Jennifer E Thorne Journal: Invest Ophthalmol Vis Sci Date: 2014-06-12 Impact factor: 4.799
Authors: Michael Yen; Jenny Chen; Somsanguan Ausayakhun; Paradee Kunavisarut; Pornpattana Vichitvejpaisal; Sakarin Ausayakhun; Choeng Jirawison; Jessica Shantha; Gary N Holland; David Heiden; Todd P Margolis; Jeremy D Keenan Journal: Am J Ophthalmol Date: 2014-10-22 Impact factor: 5.258
Authors: Kumar G Janoria; Sai H S Boddu; Zhiying Wang; Durga K Paturi; Swapan Samanta; Dhananjay Pal; Ashim K Mitra Journal: J Ocul Pharmacol Ther Date: 2009-02 Impact factor: 2.671
Authors: Sapna Gangaputra; Lea Drye; Vijay Vaidya; Jennifer E Thorne; Douglas A Jabs; Alice T Lyon Journal: Am J Ophthalmol Date: 2012-10-12 Impact factor: 5.258